Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Company Profiles

Set Alert for Emerging Company Profiles

Unicyte’s Unique Stem Cell Approach Could Cure Children With Rare Disorder

Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.

Emerging Company Profile Liver & Hepatic

Beckley Psytech Takes On Rare Disease With Psychedelics

Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.

Emerging Company Profile Neurology

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Emerging Company Profile Business Strategies

Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries

Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.

Emerging Company Profile Neurology

Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.

Emerging Company Profile Rare Diseases

Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

Emerging Company Profile Neurology

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Companies StartUps and SMEs

UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.   

Neurology Research & Development

Investors Back Microbial Specialist EnteroBiotix’s Series A Financing

Emerging Company Profile: Scotland-based EnteroBiotix will use proceeds from a successful series A financing to advance its nascent pipeline of novel high-diversity microbial therapeutics, enhancing the gut microbiome and eventually targeting multiple indications.

Financing Commercial

France’s PEP-Therapy Cell-Penetrating Peptides To Teach Cancer Cells How ‘To Die Again’

Emerging Company Profile: Armed with fresh funds, French spin-out PEP-Therapy will begin a clinical proof of concept study assessing its lead therapeutic peptide as a potential treatment for metastatic triple-negative breast cancer and platinum-resistant ovarian cancer.

Companies Clinical Trials

Hemab Launches With ‘Pipeline In An Asset’ Approach To Rare Blood Disorders

Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.

Emerging Company Profile Financing

AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest

Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register